Last reviewed · How we verify

celecoxib, esomeprazole — Competitive Intelligence Brief

celecoxib, esomeprazole (celecoxib, esomeprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID, PPI. Area: Gastroenterology, Pain management.

phase 3 NSAID, PPI COX-2, H+/K+ ATPase Gastroenterology, Pain management Small molecule Live · refreshed every 30 min

Target snapshot

celecoxib, esomeprazole (celecoxib, esomeprazole) — Chinese University of Hong Kong. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing inflammation and pain. Esomeprazole is a proton pump inhibitor that reduces stomach acid production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
celecoxib, esomeprazole TARGET celecoxib, esomeprazole Chinese University of Hong Kong phase 3 NSAID, PPI COX-2, H+/K+ ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID, PPI class)

  1. Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). celecoxib, esomeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-esomeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: